Bristol-Myers Squibb/BMY
$44.03
-0.09%-
1D1W1MYTD1YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Ticker
BMY
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
Christopher Boerner
Employees
34,100
Headquarters
Princeton, United States
Website
www.bms.com
BMY Metrics
BasicAdvanced
$89B
Market cap
-
P/E ratio
-$3.10
EPS
0.44
Beta
$2.31
Dividend rate
5.45%
Dividend yield
Price and volume
Market cap
$89B
Beta
0.4438
52-week high
$67.16
52-week low
$43.33
Average daily volume
15M
Dividend rate
$2.31
Financial strength
Current ratio
1.11
Quick ratio
0.995
Long term debt to equity
300.103
Total debt to equity
337.641
Interest coverage (TTM)
15.57%
Management effectiveness
Return on assets (TTM)
-6.35%
Return on equity (TTM)
-25.45%
Return on investment (TTM)
-8.27%
Valuation
Price to revenue (TTM)
1.96
Price to book
5.412
Price to free cash flow (TTM)
11.518
Five year average dividend yield
3.16%
Dividend yield (TTM)
5.25%
Forward dividend yield
5.45%
Growth
Revenue change (TTM)
-0.68%
Earnings per share change (TTM)
-190.34%
3-year revenue growth
1.91%
3-year dividend per share growth
8.2%
What the Analysts think about BMY
Analyst Ratings
Majority rating from 27 analysts.
Price Targets
Average projection from 21 analysts.
High $75.00
Low $37.00
$44.03
Current price
$52.25
Average price target
BMY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
3.38%
Net income
-$12B
-775.99%
Profit margin
-100.38%
-753.94%
BMY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.75
$2.00
$1.70
-$4.40
-
Expected
$1.98
$1.76
$1.53
-$4.44
$1.69
Surprise
-11.43%
13.64%
11.13%
-0.8%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $89B as of May 20, 2024.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 0 as of May 20, 2024.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is $2.31 and the yield is 5.45%. Bristol-Myers Squibb has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment date is unconfirmed.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Bristol-Myers Squibb stock price target?
The target price for Bristol-Myers Squibb (BMY) stock is $52.25, which is 18.67% above the current price of $44.03. This is an average based on projections from 21 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Bristol-Myers Squibb stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.